Literature DB >> 3695480

Are estrogen receptors cytoplasmic or nuclear? Some immunocytochemical and biochemical studies.

I Parikh1, K G Rajendran, J L Su, T Lopez, M Sar.   

Abstract

The subcellular localization of estradiol receptor (ER) has been examined using various experimental approaches. Immunocytochemical studies using the monoclonal antibody JS 34/32, raised against calf uterine cytosolic ER, yielded only equivocal results. In general, cells and tissues pretreated with estradiol showed positive immunostaining in the nuclei whereas those not exposed to the steroid did not show any staining. Nuclear translocation of ER was examined in intact MCF-7 cells using compounds which are known to influence receptor activation. When MCF-7 cells were exposed to molybdate (20 mM), nuclear translocation was completely inhibited while dithiothreitol (20 mM), dibutyryl cAMP (1 microM) and dibutyryl cGMP (1 microM) increased the translocation 2-3-fold. Phenol red, at the range of concentrations generally used in tissue culture media, also increased translocation. The physiological validity of such translocation was examined using cellular progesterone receptor (PR) synthesis as a specific parameter. When MCF-7 cells were grown in media containing phenol red for 48 h, the PR synthesis increased significantly. We further examined whether cytoskeletal proteins are involved in the translocation of ER. Colchicine, an inhibitor of microtubule assembly, inhibited translocation of ER in MCF-7 cells at 1-10 microM. PR synthesis was also inhibited by colchicine in a dose-dependent manner. It may be concluded from these and other published data that ER may not be located at all times in a single subcellular compartment but may rather exist in a dynamic equilibrium between the plasma membrane, cytoplasm and nucleus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3695480     DOI: 10.1016/0022-4731(87)90309-8

Source DB:  PubMed          Journal:  J Steroid Biochem        ISSN: 0022-4731            Impact factor:   4.292


  8 in total

1.  Immunogold labelling of the cytoplasmic estradiol receptor in resting porcine endometrium.

Authors:  W D Sierralta; H H Thole
Journal:  Cell Tissue Res       Date:  1992-10       Impact factor: 5.249

2.  Retrieval of estradiol receptor in paraffin sections of resting porcine uteri by microwave treatment. Immunostaining patterns obtained with different primary antibodies.

Authors:  W D Sierralta; H H Thole
Journal:  Histochem Cell Biol       Date:  1996-05       Impact factor: 4.304

3.  Demonstration of estrogen receptors and of estrogen responsiveness in the HKT-1097 cell line derived from diethylstilbestrol-induced kidney tumors.

Authors:  R Brohée; D Nonclercq; D N Journé; G Toubeau; P Falmagne; G Leclercq; J A Heuson-Stiennon; G Laurent
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Nov-Dec       Impact factor: 2.416

4.  Cerebral hypoperfusion increases estrogen receptor abundance in the ovine fetal brain and pituitary.

Authors:  Charles E Wood
Journal:  Neuroendocrinology       Date:  2007-12-21       Impact factor: 4.914

5.  Immunogold labelling of estradiol receptor in MCF7 cells.

Authors:  W D Sierralta; I Bönig; H H Thole
Journal:  Cell Tissue Res       Date:  1995-03       Impact factor: 5.249

6.  Immunocytology with microwave-fixed fibroblasts shows 1 alpha,25-dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors.

Authors:  J Barsony; J W Pike; H F DeLuca; S J Marx
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

7.  The role of G-protein-coupled membrane estrogen receptor in mouse Leydig cell function-in vivo and in vitro evaluation.

Authors:  M Kotula-Balak; P Pawlicki; A Milon; W Tworzydlo; M Sekula; A Pacwa; E Gorowska-Wojtowicz; B Bilinska; B Pawlicka; J Wiater; M Zarzycka; J Galas
Journal:  Cell Tissue Res       Date:  2018-06-06       Impact factor: 5.249

Review 8.  The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.

Authors:  Yating Wang; Shou-Ching Tang
Journal:  Cancer Metastasis Rev       Date:  2022-10-14       Impact factor: 9.237

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.